Oxford Financial Group Ltd. Has $1.50 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Oxford Financial Group Ltd. cut its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 11.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,192 shares of the company’s stock after selling 1,173 shares during the period. Oxford Financial Group Ltd.’s holdings in Johnson & Johnson were worth $1,502,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Morton Brown Family Wealth LLC boosted its stake in shares of Johnson & Johnson by 78.0% during the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after purchasing an additional 78 shares in the last quarter. Goodman Advisory Group LLC acquired a new stake in Johnson & Johnson during the 2nd quarter worth approximately $39,000. Cardinal Capital Management Inc. grew its holdings in Johnson & Johnson by 333.3% during the 2nd quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock worth $46,000 after acquiring an additional 200 shares during the last quarter. First Bank & Trust increased its position in Johnson & Johnson by 69.6% in the 2nd quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after acquiring an additional 156 shares during the period. Finally, Heritage Wealth Management LLC bought a new position in shares of Johnson & Johnson during the second quarter valued at $84,000. Institutional investors and hedge funds own 67.94% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on JNJ shares. StockNews.com initiated coverage on Johnson & Johnson in a report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Barclays began coverage on Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price objective for the company. SVB Leerink decreased their target price on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday. Raymond James dropped their price target on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 19th. Finally, Credit Suisse Group initiated coverage on shares of Johnson & Johnson in a research report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price objective for the company. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $181.75.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $168.31 on Tuesday. The firm has a market capitalization of $440.04 billion, a P/E ratio of 23.44, a P/E/G ratio of 3.21 and a beta of 0.56. The firm’s 50-day moving average price is $176.07 and its 200-day moving average price is $171.13. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be paid a $1.13 dividend. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.69%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 76,923 shares of Johnson & Johnson stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total value of $13,598,447.94. Following the completion of the sale, the executive vice president now owns 126,456 shares of the company’s stock, valued at approximately $22,354,891.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, EVP Jennifer L. Taubert sold 76,923 shares of the firm’s stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total value of $13,598,447.94. Following the transaction, the executive vice president now owns 126,456 shares of the company’s stock, valued at approximately $22,354,891.68. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the sale, the vice president now directly owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The disclosure for this sale can be found here. Insiders sold a total of 233,611 shares of company stock worth $40,960,735 over the last quarter. 0.35% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.